CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients

Recent years have witnessed the groundbreaking success of immune checkpoint blockage (ICB) in metastasized malignant melanoma. However, biomarkers predicting the response to ICB are still urgently needed. In the present study, we investigated CTLA4 promoter methylation (mCTLA4) in 470 malignant mela...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JCI Insight
Asıl Yazarlar: Goltz, Diane, Gevensleben, Heidrun, Vogt, Timo J., Dietrich, Joern, Golletz, Carsten, Bootz, Friedrich, Kristiansen, Glen, Landsberg, Jennifer, Dietrich, Dimo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Clinical Investigation 2018
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6124533/
https://ncbi.nlm.nih.gov/pubmed/29997292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.96793
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller